Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059091 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) and Allergies, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 334
- Enrollment target
- 20
- Study locations
NCT07059091 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) and Allergies that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 334 participants, below the 642-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT07059091, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) and Allergies, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 334 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.
Conditions Studied
Interventions
- DRUG Omalizumab (Xolair®)
- DRUG Sodium Chloride (NaCl) 0.9 %
Study Locations (20)
Illinois
- University of Illinois at Chicago - Chicago
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
New York
- Mount Sinai, Icahn School of Medicine - New York
- Columbia University - New York
- Cornell University - New York
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Health - Detroit
Pennsylvania
- Temple University - Philadelphia
- University of Pittsburgh - Pittsburgh
Alabama
- University of Alabama - Birmingham
Arizona
- University of Arizona- Tuscon - Tucson
California
- University of San Francisco - San Francisco
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2026-02-12 |
| Est. Completion | 2031-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07059091
The ClinicalTrials.gov registry entry for NCT07059091 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (48% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Omalizumab (Xolair®) is the first listed.
NCT07059091 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Illinois, New York, Michigan.
Frequently Asked Questions
What is clinical trial NCT07059091 about?
NCT07059091 is a clinical study titled "Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD". This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a fol...
What is the current status of trial NCT07059091?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 334 participants. The study started on 2026-02-12. Estimated completion is 2031-05.
What conditions does trial NCT07059091 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD), Allergies.
What interventions are being tested in trial NCT07059091?
The interventions under investigation include: Omalizumab (Xolair®) (DRUG), Sodium Chloride (NaCl) 0.9 % (DRUG).
Who is sponsoring clinical trial NCT07059091?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07059091 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 2
-
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)
COMPLETED · Phase 2
-
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
COMPLETED · Phase 2
-
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
-
Sodium Pyruvate Therapy in COPD Patients
COMPLETED · Phase 2
-
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.